911 Shares in United Therapeutics Corporation $UTHR Acquired by Waddell & Associates LLC

Waddell & Associates LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 911 shares of the biotechnology company’s stock, valued at approximately $444,000.

Several other hedge funds and other institutional investors have also modified their holdings of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $553.14 on Wednesday. The stock has a fifty day moving average price of $569.08 and a two-hundred day moving average price of $520.18. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market cap of $23.48 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 1.77 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.63 EPS. As a group, research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $547.50, for a total transaction of $5,475,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,334,610. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, June 8th. The stock was sold at an average price of $547.49, for a total value of $5,201,155.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,180,462.37. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 634,043 shares of company stock worth $357,481,310 over the last 90 days. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on UTHR shares. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.